DLL3-directed CAR T-cells
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for DLL3-directed CAR T-cells, covering 2026-03-24 to 2026-03-24. Get the full timeline:
Most recent: Clinical Trial Update: DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer [Phase 1]